Skip to content
Subscriber Only

Mabion Extends Year’s Gains to 318% as Covid Vaccine Nears

  • Vacant production facilities are key assets for Polish biotech
  • Export limits trigger pharma companies to seek new locations
UW Medicine Conducts Novavax COVID-19 Vaccine Clinical Trial

Photographer: Karen Ducey/Getty Images

Updated on

Poland’s Mabion SA expects to start commercial production of Novavax Inc.’s coronavirus vaccine quickly after it completes test trials around mid 2021 in what could be the start of multiyear cooperation between the companies.

There is “great interest” by Novavax to start production as soon as possible and its scientists are in Konstantynow Lodzki, central Poland, helping to get the process on track, Mabion board member Adam Pietruszkiewicz said in an interview.